Drug Profile


Alternative Names: Cour-NP-GLI; TIMP-GLIA; TIMP/Gliadin; Toleragenic Immune Modifying nanoParticles - coeliac disease

Latest Information Update: 11 Apr 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Cour Pharmaceutical Development
  • Developer Cour Pharmaceutical Development; University of Helsinki
  • Class Polymers; Proteins
  • Mechanism of Action Gliadin inhibitors; T cell activation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Coeliac disease

Most Recent Events

  • 06 Apr 2018 Cour Pharmaceutical plans a phase I trial for Coeliac Disease (In volunteers) in Australia (IV) in April 2018 (ACTRN12618000459224p)
  • 09 Feb 2018 Phase-I clinical trials in Coeliac disease in USA (IV) (NCT03486990)
  • 01 Nov 2013 Cour Pharma enters into option and evaluation alliances with two undisclosed pharmaceutical companies for development of products in Coeliac disease
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top